Loading…
Octapharma confirmed a EUR 21 million investment to build a new multi-function facility in Springe, Germany, including a new production line for human normal immunoglobulin panzyga and increased capacity for human albumin albunorm. Completion is expected in 2019.
| Site | Largest | Latest |
|---|---|---|
| Springe, Germany | $24.5M | 2018-09-21 |